Corporate Overview

Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The Company sells AMNIOEXCEL® amniotic allograft membrane and AMNIOMATRIX® amniotic allograft suspension into the $500 million market for skin substitute products. Derma Sciences’ MEDIHONEY® product line is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is a gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. The Company also offers a full product line of traditional dressings.

DSCI (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$42.29
Change (%) Stock is Down 0.31 (0.73%)
Volume442,065
Data as of 03/29/17 4:00 p.m. ET
Minimum 20 minute delay

There are currently no events scheduled.


Previous Webcasts

There are currently no webcasts displayed.

SEC Filings

Filing DateFormDescriptionFiling GroupDownloads
03/15/17CT ORDERCT ORDEROther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/10/17SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
03/07/17EFFECTEFFECTOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
Fundamentals, Copyright Thomson Reuters Corporation